C Potey1, T Ouk1, O Petrault1, M Petrault1, V Berezowski1, J Salleron2, R Bordet1, S Gautier1. 1. U1171 - Medical Pharmacology Department, Faculty of Medicine, University of Lille 2 - Lille University Hospital, Lille, France. 2. EA2694 - Biostatistics Department, Faculty of Medicine, University of Lille 2 - Lille University Hospital, Lille, France.
Abstract
BACKGROUND AND PURPOSE: From the clinical and experimental data available, statins appear to be interesting drug candidates for preventive neuroprotection in ischaemic stroke. However, their acute protective effect is, as yet, unconfirmed. EXPERIMENTAL APPROACH: Male C57Bl6/JRj mice were subjected to middle cerebral artery occlusion and treated acutely with atorvastatin (10-20 mg·kg(-1) day(-1) ; 24 or 72 h). Functional recovery (neuroscore, forelimb gripping strength and adhesive removal test) was assessed during follow-up and lesion volume measured at the end. Vasoreactivity of the middle cerebral artery (MCA), type IV collagen and FITC-dextran distribution were evaluated to assess macrovascular and microvascular protection. Activated microglia, leucocyte adhesion and infiltration were chosen as markers of inflammation. KEY RESULTS: Acute treatment with atorvastatin provided parenchymal and cerebral protection only at the higher dose of 20 mg·kg(-1) ·day(-1) . In this treatment group, functional recovery was ameliorated, and lesion volumes were reduced as early as 24 h after experimental stroke. This was associated with vascular protection as endothelial function of the MCA and the density and patency of the microvascular network were preserved. Acute atorvastatin administration also induced an anti-inflammatory effect in association with parenchymal and vascular mechanisms; it reduced microglial activation, and decreased leucocyte adhesion and infiltration. CONCLUSIONS AND IMPLICATIONS: Acute atorvastatin provides global cerebral protection, but only at the higher dose of 20 mg·kg(-1) ·day(-1) ; this was associated with a reduction in inflammation in both vascular and parenchymal compartments. Our results suggest that atorvastatin could also be beneficial when administered early after stroke.
BACKGROUND AND PURPOSE: From the clinical and experimental data available, statins appear to be interesting drug candidates for preventive neuroprotection in ischaemic stroke. However, their acute protective effect is, as yet, unconfirmed. EXPERIMENTAL APPROACH: Male C57Bl6/JRj mice were subjected to middle cerebral artery occlusion and treated acutely with atorvastatin (10-20 mg·kg(-1) day(-1) ; 24 or 72 h). Functional recovery (neuroscore, forelimb gripping strength and adhesive removal test) was assessed during follow-up and lesion volume measured at the end. Vasoreactivity of the middle cerebral artery (MCA), type IV collagen and FITC-dextran distribution were evaluated to assess macrovascular and microvascular protection. Activated microglia, leucocyte adhesion and infiltration were chosen as markers of inflammation. KEY RESULTS: Acute treatment with atorvastatin provided parenchymal and cerebral protection only at the higher dose of 20 mg·kg(-1) ·day(-1) . In this treatment group, functional recovery was ameliorated, and lesion volumes were reduced as early as 24 h after experimental stroke. This was associated with vascular protection as endothelial function of the MCA and the density and patency of the microvascular network were preserved. Acute atorvastatin administration also induced an anti-inflammatory effect in association with parenchymal and vascular mechanisms; it reduced microglial activation, and decreased leucocyte adhesion and infiltration. CONCLUSIONS AND IMPLICATIONS: Acute atorvastatin provides global cerebral protection, but only at the higher dose of 20 mg·kg(-1) ·day(-1) ; this was associated with a reduction in inflammation in both vascular and parenchymal compartments. Our results suggest that atorvastatin could also be beneficial when administered early after stroke.
Authors: Xian Shuang Liu; Zheng Gang Zhang; Li Zhang; Daniel C Morris; Alissa Kapke; Mei Lu; Michael Chopp Journal: J Cereb Blood Flow Metab Date: 2006-06 Impact factor: 6.200
Authors: I-Chen Yu; Ping-Chang Kuo; Jui-Hung Yen; Hallel C Paraiso; Eric T Curfman; Benecia C Hong-Goka; Robert D Sweazey; Fen-Lei Chang Journal: Transl Stroke Res Date: 2017-06-17 Impact factor: 6.829
Authors: C Potey; T Ouk; O Petrault; M Petrault; V Berezowski; J Salleron; R Bordet; S Gautier Journal: Br J Pharmacol Date: 2015-10-06 Impact factor: 8.739
Authors: Ana Lucía Rodríguez-Perea; Johanna Gutierrez-Vargas; Gloria Patricia Cardona-Gómez; Carlos Julio Montoya Guarin; Mauricio Rojas; Paula Andrea Velilla Hernández Journal: J Neuroimmune Pharmacol Date: 2016-09-10 Impact factor: 4.147
Authors: Bartosz Sokół; Norbert Wąsik; Roman Jankowski; Marcin Hołysz; Witold Mańko; Robert Juszkat; Tomasz Małkiewicz; Paweł P Jagodziński Journal: Biomed Res Int Date: 2017-05-29 Impact factor: 3.411
Authors: Joshua S Catapano; Candice L Nguyen; Andre A Wakim; Felipe C Albuquerque; Andrew F Ducruet Journal: Front Neurol Date: 2020-10-20 Impact factor: 4.003